VYNE THERAPEUTICS INC. overview

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2 nd Annual...

2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024 Ended 2023 with $93.3 million of cash, cash equivalents, restricted cash and marketable securities, providing runway through the end of 2025 and multiple expected clinical milestones BRIDGEWATER, N.J., Feb....

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral...

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44 th Annual Health Care Conference at the Boston Marriott Copley Place in Boston,...

VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical results Program is on track for Phase 2b initiation in Q2 BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory...

BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. “We are pleased to welcome Dr. Borowski to our Board of Directors during this important...

Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024 BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a...

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory...